A carregar...
Myasthenia Gravis Induced by Nivolumab: A Case Report
Nivolumab is a programmed cell death receptor (PD-1) inhibitor therapy for aggressive cancers; however, it poses a risk of immune-related adverse side effects. We present a 73-year-old male with renal cell carcinoma who developed myasthenia gravis (MG) after being treated with nivolumab, proven by a...
Na minha lista:
| Publicado no: | Cureus |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cureus
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5690486/ https://ncbi.nlm.nih.gov/pubmed/29159009 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.1702 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|